John C Burnett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6614963/publications.pdf

Version: 2024-02-01

41 papers	3,316 citations	257450 24 h-index	361022 35 g-index
45 all docs	45 docs citations	45 times ranked	5167 citing authors

#	Article	IF	Citations
1	RNA-Based Therapeutics: Current Progress and Future Prospects. Chemistry and Biology, 2012, 19, 60-71.	6.0	804
2	Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity. Cell, 2005, 122, 169-182.	28.9	599
3	Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology Journal, 2011, 6, 1130-1146.	3.5	380
4	Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals, 2013, 6, 85-107.	3.8	171
5	Current Progress of RNA Aptamer-Based Therapeutics. Frontiers in Genetics, 2012, 3, 234.	2.3	111
6	Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Molecular Therapy, 2016, 24, 488-498.	8.2	109
7	Control of Stochastic Gene Expression by Host Factors at the HIV Promoter. PLoS Pathogens, 2009, 5, e1000260.	4.7	98
8	Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants. Journal of Virology, 2010, 84, 5958-5974.	3.4	97
9	HIV Promoter Integration Site Primarily Modulates Transcriptional Burst Size Rather Than Frequency. PLoS Computational Biology, 2010, 6, e1000952.	3.2	95
10	Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Research, 2013, 41, 4266-4283.	14.5	73
11	Cell-Specific RNA Aptamer against Human CCR5 Specifically Targets HIV-1 Susceptible Cells and Inhibits HIV-1 Infectivity. Chemistry and Biology, 2015, 22, 379-390.	6.0	71
12	RNA interference approaches for treatment of HIV-1 infection. Genome Medicine, 2015, 7, 50.	8.2	69
13	High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. Scientific Reports, 2016, 6, 33697.	3.3	66
14	Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Research, 2013, 41, 6209-6221.	14.5	59
15	Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID â€œMeet the Expertsâ€•2015 Workshop Summary. AIDS Research and Human Retroviruses, 2016, 32, 109-119.	1.1	57
16	AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments. Cell Systems, 2016, 3, 62-70.	6.2	55
17	The role of antisense long noncoding RNA in small RNA-triggered gene activation. Rna, 2014, 20, 1916-1928.	3.5	46
18	Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology, 2013, 10, 86.	2.0	45

#	Article	IF	Citations
19	HIV Evades RNA Interference Directed at TAR by an Indirect Compensatory Mechanism. Cell Host and Microbe, 2008, 4, 484-494.	11.0	44
20	Exosome-mediated stable epigenetic repression of HIV-1. Nature Communications, 2021, 12, 5541.	12.8	41
21	Creating genetic resistance to HIV. Current Opinion in Immunology, 2012, 24, 625-632.	5.5	39
22	HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. Journal of Virology, 2018, 92, .	3.4	36
23	Identification of a therapeutic interfering particleâ€"A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. Cell, 2021, 184, 6022-6036.e18.	28.9	36
24	Aptamerâ€"siRNA Chimeras for HIV. Advances in Experimental Medicine and Biology, 2015, 848, 211-234.	1.6	28
25	Novel Humanized Peripheral Blood Mononuclear Cell Mouse Model with Delayed Onset of Graft-versus-Host Disease for Preclinical HIV Research. Journal of Virology, 2022, 96, JVI0139421.	3.4	11
26	CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. Molecular Therapy - Methods and Clinical Development, 2022, 24, 321-331.	4.1	11
27	Stem cells, ribozymes and HIV. Gene Therapy, 2009, 16, 1178-1179.	4.5	10
28	Mutual Information Analysis Reveals Coevolving Residues in Tat That Compensate for Two Distinct Functions in HIV-1 Gene Expression. Journal of Biological Chemistry, 2012, 287, 7945-7955.	3.4	10
29	Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation. International Journal of Molecular Sciences, 2022, 23, 6568.	4.1	9
30	Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells and Cloning: Advances and Applications, 2015, 8, 109.	2.3	8
31	Nucleolar Localization of HIV-1 Rev Is Required, Yet Insufficient for Production of Infectious Viral Particles. AIDS Research and Human Retroviruses, 2018, 34, 961-981.	1.1	7
32	Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR TÂcells with CMV vaccine. Molecular Therapy - Methods and Clinical Development, 2022, 25, 344-359.	4.1	6
33	693. Potent and Targeted Activation of Latent HIV-1 Using Multiplexed Guide RNAs and the CRISPR/dCas9 Activator Complex. Molecular Therapy, 2015, 23, S276.	8.2	5
34	CRED9: a differentially expressed elncRNA regulates expression of transcription factor CEBPA. Rna, 2021, 27, 891-906.	3.5	5
35	Biomolecular Therapeutics for HIV. , 2018, , 541-567.		2
36	Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model. Comparative Medicine, 2014, 64, 179-85.	1.0	2

#	Article	IF	Citations
37	580. In Vivo Analyses of Aptamers and siRNA Therapeutics Against HIV-1 in Humanized Mouse Model. Molecular Therapy, 2015, 23, S231.	8.2	0
38	692. A Novel RNAi Trigger Design Retains Potent, Target Specific Activity Despite Emerging Mutations in the Target Site. Molecular Therapy, 2015, 23, S276.	8.2	0
39	581. Exploring Potency of Small RNAs for HIV Latency Reactivation. Molecular Therapy, 2015, 23, S231.	8.2	0
40	RNA Interference-Based Gene Therapy Strategies for the Treatment of HIV Infection. , 2015, , 1033-1044.		0
41	LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds. Methods in Molecular Biology, 2016, 1354, 255-264.	0.9	0